Rosmantuzumab

N/A

Report date: 2022/10/25 13:05:57

Base Information

Drug NameRosmantuzumab
Drug Alias NameOMP-131R10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionR-spondin-3 inhibitorsWnt signalling pathway inhibitors
TargetsR-spondin-3
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals IncCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncomed Pharmaceuticals IncCelgene Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursColorectal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A